Mark T. Bilodeau

5.9k total citations · 3 hit papers
67 papers, 4.6k citations indexed

About

Mark T. Bilodeau is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Mark T. Bilodeau has authored 67 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 24 papers in Organic Chemistry and 13 papers in Cellular and Molecular Neuroscience. Recurrent topics in Mark T. Bilodeau's work include Neuroscience and Neuropharmacology Research (10 papers), Receptor Mechanisms and Signaling (10 papers) and Pharmacological Receptor Mechanisms and Effects (8 papers). Mark T. Bilodeau is often cited by papers focused on Neuroscience and Neuropharmacology Research (10 papers), Receptor Mechanisms and Signaling (10 papers) and Pharmacological Receptor Mechanisms and Effects (8 papers). Mark T. Bilodeau collaborates with scholars based in United States, Canada and Ireland. Mark T. Bilodeau's co-authors include David A. Evans, Margaret M. Faul, Samuel J. Danishefsky, Fèlix Urpı́, Benjamin A. Anderson, David M. Barnes, Peter J. Manley, George D. Hartman, Todd C. Somers and Dale L. Rieger and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Mark T. Bilodeau

67 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glycals in Organic Synthesis: The Evolution of Comprehensive Strategies for the Assembly of Oligosaccharides and Glycoconjugates of Biological Consequence

1996 586 citations Mark T. Bilodeau et al. profile →
Development of the Copper-Catalyzed Olefin Aziridination Reaction

1994 555 citations Mark T. Bilodeau et al. profile →
Bis(oxazoline)-copper complexes as chiral catalysts for the enantioselective aziridination of olefins

1993 473 citations Mark T. Bilodeau et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark T. Bilodeau United States	30	3.4k	2.0k	458	287	259	67	4.6k
Roland E. Dolle United States	42	2.8k 0.8×	2.8k 1.4×	187 0.4×	553 1.9×	371 1.4×	149	5.1k
Wenhu Duan China	33	1.9k 0.5×	1.5k 0.7×	378 0.8×	304 1.1×	237 0.9×	109	3.4k
Jeffrey A. Dodge United States	31	1.1k 0.3×	1.4k 0.7×	205 0.4×	124 0.4×	364 1.4×	68	3.4k
Anthony C. Willis Australia	36	2.3k 0.7×	1.1k 0.6×	1.2k 2.6×	226 0.8×	483 1.9×	109	4.6k
Joseph M. Ready United States	36	2.7k 0.8×	902 0.4×	674 1.5×	226 0.8×	153 0.6×	101	4.1k
Joseph A. Kozlowski United States	26	1.1k 0.3×	732 0.4×	216 0.5×	319 1.1×	282 1.1×	69	2.4k
Haitao Ji United States	35	1.3k 0.4×	2.7k 1.3×	164 0.4×	120 0.4×	685 2.6×	97	4.8k
J. GORÉ France	32	2.6k 0.8×	932 0.5×	446 1.0×	105 0.4×	160 0.6×	199	3.8k
Milton L. Brown United States	35	1.1k 0.3×	2.2k 1.1×	106 0.2×	334 1.2×	688 2.7×	109	3.8k
Donald S. Karanewsky United States	30	1.1k 0.3×	1.8k 0.9×	125 0.3×	218 0.8×	362 1.4×	77	3.0k

Countries citing papers authored by Mark T. Bilodeau

Since Specialization

Citations

This map shows the geographic impact of Mark T. Bilodeau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Bilodeau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Bilodeau more than expected).

Fields of papers citing papers by Mark T. Bilodeau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Bilodeau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Bilodeau. The network helps show where Mark T. Bilodeau may publish in the future.

Co-authorship network of co-authors of Mark T. Bilodeau

This figure shows the co-authorship network connecting the top 25 collaborators of Mark T. Bilodeau. A scholar is included among the top collaborators of Mark T. Bilodeau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark T. Bilodeau. Mark T. Bilodeau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

White, Brian H., et al.. (2020). Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors. Molecular Cancer Therapeutics. 19(8). 1613–1622. 9 indexed citations

White, Brian H., James M. Quinn, Rossitza Alargova, et al.. (2019). Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. Molecular Cancer Therapeutics. 18(11). 1926–1936. 54 indexed citations

Nanda, Kausik K., Darrell A. Henze, Kimberly Della Penna, et al.. (2013). Benzimidazole CB2 agonists: Design, synthesis and SAR. Bioorganic & Medicinal Chemistry Letters. 24(4). 1218–1221. 22 indexed citations

Kuduk, Scott D., Ronald K. Chang, Christina N. Di Marco, et al.. (2011). Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3). Bioorganic & Medicinal Chemistry Letters. 21(14). 4255–4258. 16 indexed citations

Melamed, Jeffrey Y., Nathan R. Kett, Anthony L. Gotter, et al.. (2010). Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(15). 4700–4703. 21 indexed citations

Kuduk, Scott D., Christina N. Di Marco, William J. Ray, et al.. (2010). N-Heterocyclic derived M1 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 20(4). 1334–1337. 25 indexed citations

Kuduk, Scott D., Christina N. Di Marco, William J. Ray, et al.. (2010). Fused heterocyclic M1 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 21(9). 2769–2772. 14 indexed citations

Haskell, Kathleen, Bonnie J. Howell, Raymond C. F. Jones, et al.. (2010). An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biology & Therapy. 9(7). 493–503. 53 indexed citations

Kuduk, Scott D., Robert M. DiPardo, Douglas C. Beshore, et al.. (2010). Hydroxy cycloalkyl fused pyridone carboxylic acid M1 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 20(8). 2538–2541. 15 indexed citations

10.

Kuduk, Scott D., Christina N. Di Marco, Ronald K. Chang, et al.. (2010). Heterocyclic fused pyridone carboxylic acid M1 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 20(8). 2533–2537. 21 indexed citations

11.

Kuduk, Scott D., Christina N. Di Marco, William J. Ray, et al.. (2009). Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding. Bioorganic & Medicinal Chemistry Letters. 20(2). 657–661. 20 indexed citations

12.

Bilodeau, Mark T., J. M. HOFFMAN, Peter J. Manley, et al.. (2008). Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorganic & Medicinal Chemistry Letters. 18(11). 3178–3182. 56 indexed citations

13.

Wu, Zhicai, R. Robinson, Sheng Fu, et al.. (2008). Development of Pyridopyrimidines as Potent Akt1/2 Inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(4). 1274–1279. 23 indexed citations

14.

Bell, Ian M. & Mark T. Bilodeau. (2008). The Impact of IKr Blockade on Medicinal Chemistry Programs. Current Topics in Medicinal Chemistry. 8(13). 1128–1139. 7 indexed citations

15.

Wu, Zhicai, R. Robinson, Sheng Fu, et al.. (2007). Rapid assembly of diverse and potent allosteric Akt inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(6). 2211–2214. 41 indexed citations

16.

Nanda, Kausik K., Matthew J. Cato, Stefanie A. Kane, et al.. (2006). Potent antagonists of the Kv1.5 potassium channel: Synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides. Bioorganic & Medicinal Chemistry Letters. 16(22). 5897–5901. 11 indexed citations

17.

Bilodeau, Mark T., Kathleen Coll, William R. Huckle, et al.. (2003). Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR. Bioorganic & Medicinal Chemistry Letters. 13(15). 2485–2488. 13 indexed citations

18.

Manley, Peter J., Mark T. Bilodeau, Kathleen Coll, et al.. (2003). 2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(10). 1673–1677. 23 indexed citations

19.

Hartman, George D., Mark E. Fraley, & Mark T. Bilodeau. (2002). Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opinion on Investigational Drugs. 11(6). 737–745. 39 indexed citations

20.

Bilodeau, Mark T., et al.. (1999). Use of clonidine as a component of the peribulbar block in patients undergoing cataract surgery1. Regional Anesthesia & Pain Medicine. 24(5). 426–429. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact